Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $12.43, but opened at $11.9150. Sysmex shares last traded at $11.85, with a volume of 103,093 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Sysmex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold”.

Sysmex Trading Down 0.9%

The business has a 50 day moving average of $10.82 and a 200 day moving average of $9.50. The firm has a market capitalization of $7.44 billion, a price-to-earnings ratio of 28.14 and a beta of 1.09. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. The company had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, research analysts predict that Sysmex Corporation ADR will post 0.38 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.